Abstract:
본 발명은 꾸지나무 추출물 및 인동 추출물을 유효성분으로 포함하는 염증 및/또는 통증의 경감 또는 치료를 위한 의약 조성물에 관한 것이다. 본 발명은, 꾸지나무의 프레닐레이티드 플라보노이드-농축 추출물 및 인동의 에탄올 추출물의 병용 투여가 각각의 추출물을 단독 투여한 경우에 비하여 시험관 내 및 생체 내 시험에서 현저하게 우수하고 상승적인 항염증 및 진통효과를 보인다는 것을 밝힌 것을 기초로 한다. 본 발명의 의약조성물은 예를 들어, 기관지염, 천식, 만성폐쇄성폐질환, 호흡기계 염증성 질환, 류마티스성 관절염, 골관절염, 퇴행성 관절염, 다발성 관절염, 급성염증, 알러지성 염증, 건선 등의 피부질환, 요통, 발치후 동통, 두통, 수술 후 통증 및 염증, 치통, 생리통 등 소염진통효과를 필요로 하는 각종 질병의 치료에 사용될 수 있다. 꾸지나무, 인동, 항염증, 천식, 진통, 만성폐쇄성폐질환(COPD)
Abstract:
본 발명은 에스-알릴-엘-시스테인(S-allyl-L-cysteine)을 유효성분으로 함유하는 항헬리코박터 활성 또는 위점막 보호기능을 갖는 조성물 또는 위장질환의 예방, 개선 또는 치료용 조성물 및 이를 사용하는 방법에 관한 것이다. 알릴시스테인, 헬리코박터, 위장질환, 위궤양, 위염
Abstract:
PURPOSE: A sustained release formulation containing nicametate or pharmaceutically acceptable salt thereof is provided to maintain constant blood glucose for 24 hours. CONSTITUTION: A sustained release formulation contains 10-70 weight% of nicametate or pharmaceutically acceptable salt thereof and 5-50 weight% of hydrophilic polymer of hydroxypropylmethycellulose, polyethylene oxide, carbomer, or polyethylene glycol alginate. The sustained release formulation contains microcrystalline cellulose as an excipient. The pharmaceutically acceptable salt of nicametate is citric acid nicametate.
Abstract:
PURPOSE: A pharmaceutical composition containing Broussonetia papyrifera (L.) Vent. (Moraceae) extract and Lonicera japonica extract is provided to relieve pain and/or inflammation. CONSTITUTION: A pharmaceutical composition for preventing, relieving, or treating inflammation and/or pain contains: a first material selected from Broussonetia papyrifera (L.) Vent. (Moraceae) extract, fraction, and pharmaceutically acceptable salt thereof; and a second material selected from Lonicera japonica extract and pharmaceutically acceptable salt thereof.
Abstract:
PURPOSE: A medicinal composition containing Broussonetia papyrifera and Lonicera japonica extract is provided to ensure anti-inflammation and analgesic effects. CONSTITUTION: A medicinal composition for preventing, relieving, treating inflammation and/or pain contains a first substance selected from Broussonetia papyrifera extract, fraction of the extract, and pharmaceutically acceptable salt thereof; a second substance of Lonicera japonica extract of pharmaceutically acceptable salt thereof as an active ingredient. The medicinal composition further contains pharmaceutically acceptable carrier.
Abstract:
PURPOSE: A composition containing S-allyl-L-cysteine or gastric mucous is provided to suppress helicobacter infection and to prevent gastric damage. CONSTITUTION: A pharmaceutical composition with anti-helicobacter activity contains S-allyl-L-cysteine, pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient. A pharmaceutical composition for preventing or treating gastrointestinal disorder contains S-allyl-L-cysteine, pharmaceutically acceptable salt, solvate, or hydrate thereof as an active ingredient. S-allyl-L-cysteine is isolated and purified from Allium genus plants.